Navigation Links
Cell surface mutation protects against common type of malaria
Date:12/1/2011

A mutation on the surface of human red blood cells provides protection against malaria caused by the parasite Plasmodium vivax, research led by Case Western Reserve University School of Medicine shows.

The minute change, at a single position of red blood cell surface protein called the Duffy blood-group antigen, has been known for years. But the researchers found this difference makes it harder for the parasite to lock onto the cell and gain entry.

No entry, no infection.

The research is now published online in the Early Edition of the Proceedings of the National Academy of Sciences.

"The finding has practical implications as medical researchers continue attempts to develop a vaccine for vivax malaria," said Christopher King, a professor of international health, medicine and pathology at the Center for Global Health and Diseases at Case Western Reserve University School of Medicine, and lead author.

The protective aspect of the mutation was discovered in campus labs and confirmed through a population study in the Amazon region of Brazil.

Malaria is caused by four different parasites; the majority of cases in Asia and the Americas are caused by P. vivax.

"Plasmodium vivax carries a Duffy binding protein that binds to the Duffy antigen on the surface of the red cell, a critical step to invading the cell," Dr. King explained. "Both parasite and human proteins appear to be needed for the parasite to invade the cell."

King's lab had been studying the parasite's protein, as a target for a vaccine. He teamed with Peter A. Zimmerman, a professor of international health, genetics and biology, also at the Center for Global Health and Diseases. Zimmerman's lab was studying the mutation in the DNA sequence of Duffy blood group gene.

While investigating the binding process, they found that Duffy binding protein interaction with red blood cells varied between samples.

They performed the genetic tests for the single-point mutation. Antigens with the mutation are called Duffy 'A' and those without, Duffy 'B'.

They found the parasite bound to red blood cells expressing Duffy 'B' about twice as often as the parasite bound to cells expressing Duffy 'A'.

The researchers wanted to see if the finding translated to real life.

They collaborated with Marcelo U. Ferreira, an investigator at the Department of Parasitology, Institute of Biomedical Sciences, University of Sao Paulo, to analyze data from 400 individuals tracked for malaria infections for more than a year in northwest Brazil.

In northwestern Brazil, where a mixture of Duffy 'A' and 'B' variants are inherited, the researchers found that people expressing the Duffy 'B' variant experience P. vivax malaria more often than those who expressed the Duffy 'A' variant.

"Therefore, stronger binding to Duffy 'B' leads to greater success at red cell invasion and more vivax malaria, Zimmerman said. "Seen from the other side of this relationship, weaker binding to Duffy 'A' appears to reduce red cell invasion and is therefore protective against vivax malaria."

The analysis showed that those with the Duffy 'A'/Duffy 'A' genotype had a 29 percent reduced risk of vivax malaria. Those who had the Duffy 'A'/Duffy 'B-negative' (a varient that has no antigen) genotype, had an 80 percent reduced risk. Reduced risk was not associated with an increase in antibodies in either case.

Those with Duffy 'B'/Duffy 'B' or Duffy 'B'/Duffy 'B-negative' genotypes had an increased risk of 220 to 270 percent for vivax malaria.

A vaccine's effectiveness therefore may depend on whether a recipient carries one or two copies of the Duffy 'A' or 'B' mutation in his DNA Dr. King said.

"The Duffy 'B' variant is ancestral to Duffy 'A'. We know this because all non-human primates carry the Duffy 'B' variant," Zimmerman said. "So a case can be made for the Duffy 'A' variant arising as protection from vivax malaria."

In a further analysis, the researchers found no association with the Duffy 'A' varient and Plasmodium falciparum, the parasite that causes the majority of infections in sub-Saharan Africa and the cause of 66 cases among the 400 individuals studied.


'/>"/>

Contact: Kevin Mayhood
kevin.mayhood@case.edu
216-368-4442
Case Western Reserve University
Source:Eurekalert

Related biology news :

1. Surface tension drives segregation within cell mixtures
2. Surface-level ozone pollution set to reduce tree growth 10 percent by 2100
3. NIST-Cornell team builds worlds first nanofluidic device with complex 3-D surfaces
4. Sugar on bacteria surface serves as base for a web of resistance
5. EPAs new green parking lot allows scientists to study permeable surfaces that may help the environment
6. Multiple health concerns surface as winter, vitamin D deficiences arrive
7. Water may not run uphill, but it practically flies off new surface
8. 40 percent of surface disinfectants ineffective in eliminating viruses that cause gastroenteritis
9. Helping the NRC look below the surface
10. Invasive kudzu is major factor in surface ozone pollution, study shows
11. New model is proposed to explain absence of organic compounds on surface of Mars
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2016)... SAN FRANCISCO , June 16, 2016 /PRNewswire/ ... Market size is expected to reach USD ... report by Grand View Research, Inc. Technological proliferation ... and banking applications are expected to drive the ... ) , The development of ...
(Date:6/9/2016)... , June 9, 2016 ... deploy Teleste,s video security solution to ensure the safety of ... during the major tournament Teleste, an ... systems and services, announced today that its video security solution ... to back up public safety across the country. The ...
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created ... services and solutions to the healthcare market. The company's primary focus is on ... sales and marketing strategies that are necessary to help companies efficiently bring their ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology: